All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019
Maria-Bernarda Requena(Inserm), Karine Lacombe(Inserm), Marina B. Klein(Royal Victoria Regional Health Centre), Rachel Sacks‐Davis(Burnet Institute), Juan Berenguer(Instituto de Salud Carlos III), Ashleigh C. Stewart(Burnet Institute), Inmaculada Jarrín(Instituto de Salud Carlos III), Maria Prins(University of Amsterdam), Dominique Salmon(Assistance Publique – Hôpitaux de Paris), Camélia Protopopescu(Inserm), Daniela K van Santen(Burnet Institute), Patrizia Carrieri(Inserm), Andri Rauch(University of Bern), Linda Wittkop(Université de Bordeaux), Marc van der Valk(Academic Medical Center), Margaret Hellard(The Alfred Hospital)
Cited by 5
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777